Breast cancer vaccines
What recent studies tell us about vaccine targets, immune responses and the data still missing.
· 16 pages · 37 sources
AI-assisted literature summary. Not peer reviewed or medical advice.
Works.
A summary of recent works.
Open questions.
Which targets?
Pair tumor and normal samples with HLA and presented-peptide data. Prediction alone does not establish a safe target.
Which immune responses?
Link antigen-specific T cells to tumor recognition and immune escape, including negative results.
Which outcomes?
Connect treatment, serial samples and long-term follow-up. Immune activity alone does not establish clinical benefit.
Selected studies.
- Nature2026
Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC (opens in a new tab)
Early clinical study; not randomized proof of reduced recurrence.
- Genome Medicine2024
Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients (opens in a new tab)
Early clinical study of paired sequencing, personalized vaccination and immune responses.
- Journal of Clinical Investigation2024 issue
Breast cancer immunopeptidomes contain numerous shared tumor antigens (opens in a new tab)
Antigen-presentation study, not a vaccine efficacy trial.